N4 Pharma (N4P), the specialist pharmaceutical company developing Nuvec®, announced the acquisition of a controlling interest, through a subscription for new ordinary shares, in Nanogenics Limited, a company with a complementary
N4 Pharma (N4P), the specialist pharmaceutical company developing Nuvec®, announced the acquisition of a controlling interest, through a subscription for new ordinary shares, in Nanogenics Limited, a company with a complementary
Future Metals (FME), announced enhanced metallurgical recoveries from the leaching of flotation tailings, reagent optimisation test work and the chromite concentrate potential for its wholly owned Panton Project.
Zak Mir takes a charting look at some of the most followed small caps on the London stock market. Today’s charts are FTSE 100, Dax, Dow, Bitcoin, Argo, Aura, Baron,
At its Annual General Meeting (“AGM”) which is being held later this morning, David Coghlan, the Chairman of Synectics plc (AIM: SNX), a leader in the design, integration and support